Actively Recruiting
Immune Study of Rare Soft Tissue Sarcoma Subtypes in Adults A Multi-Center Project by the French Sarcoma Group
Led by Institut Claudius Regaud · Updated on 2026-02-10
400
Participants Needed
20
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying rare subtypes of soft tissue sarcoma to better understand their clinical and biological characteristics. This is a translational, open-label study involving both prospective and retrospective cohorts, aiming to include 500 patients. The study includes patients with localized, locally advanced, or metastatic disease and seeks to evaluate outcomes such as metastasis-free survival and progression-free survival over 60 months. Patients will be enrolled from multiple centers, with 400 patients included prospectively during routine care or clinical studies, and 100 patients identified retrospectively from existing clinical databases. Tumor specimens and blood samples will be collected at diagnosis, after treatment completion or tumor evaluation, and at disease progression. Clinical and biological data will be gathered at baseline and regularly every 2 to 3 months for up to 5 years. Participants will undergo assessments including tumor specimen collection, blood sampling, and regular clinical evaluations to monitor disease progression and treatment effects. Researchers will measure survival outcomes and biological markers such as Cancer-Testis Antigens and the CINSARC signature. The study involves long-term follow-up of up to 60 months per patient to observe overall survival and other key outcomes.
CONDITIONS
Brief Title
Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group
Research Team
T
Thibaud VALENTIN
F
Frédéric CHIBON
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here